Biogen Inc. $BIIB Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 4.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 277,285 shares of the biotechnology company’s stock after selling 11,852 shares during the quarter. Fisher Asset Management LLC owned approximately 0.19% of Biogen worth $38,842,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new stake in Biogen during the second quarter worth about $25,000. Rothschild Investment LLC grew its stake in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 88 shares during the period. Accredited Wealth Management LLC increased its holdings in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares during the last quarter. NewSquare Capital LLC raised its position in shares of Biogen by 134.6% during the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares during the period. Finally, WFA of San Diego LLC acquired a new position in Biogen in the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Down 2.1%

Shares of NASDAQ:BIIB opened at $184.02 on Wednesday. The firm has a market capitalization of $27.01 billion, a PE ratio of 20.89, a price-to-earnings-growth ratio of 1.49 and a beta of 0.15. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The firm’s 50-day moving average is $182.43 and its two-hundred day moving average is $164.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the business posted $3.44 earnings per share. The business’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Piper Sandler raised their target price on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research note on Monday, February 9th. Barclays assumed coverage on Biogen in a research report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price objective for the company. Stifel Nicolaus upped their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Guggenheim increased their target price on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Truist Financial boosted their price target on shares of Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $205.04.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.18% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.